Herpes infections and allergic diseases in children

Cover Page

Abstract


The frequency of allergic pathology increases significantly every year. Herpetic infection is a constant companion of a person. Given the high percentage of herpes viruses infected, as well as their almost lifelong persistence in patients, the Association of herpes infections and allergic diseases is particularly relevant. Most often, herpes infections complicate the course of atopic dermatitis in children, often leading to the development of both acute and recurrent herpetic eczema. Chickenpox in children with atopic dermatitis is more severe, often complicated by the addition of a secondary bacterial infection. It is proved that herpes infections worsen the course of bronchial asthma, and can also trigger the development of acute and chronic urticaria. From the point of view of treatment of atopic diseases associated with herpes infections, in addition to standard treatment, it is necessary to conduct pathogenetic antiviral therapy when planning therapy.


Full Text

Restricted Access

About the authors

Anna V. Maximova

Scientific and Clinical Advisory Center of Allergy and Immunology

Author for correspondence.
Email: a.maksimova@adair.ru
ORCID iD: 0000-0002-7964-8867

Russian Federation, Moscow

Cand. Sci. (Med.)

Yury S. Smolkin

Scientific and Clinical Advisory Center of Allergy and Immunology; State Research Center «Institute of Immunology»

Email: a.maksimova@adair.ru
ORCID iD: 0000-0001-7876-6258

Russian Federation, Moscow

D. Sci. (Med.), Prof.

References

  1. Patel R et al. 2017 European guidelines for the management of genital herpes. Int J STD AIDS 2017; 28 (14): 1366–79.
  2. Von Hertzen LC. Puzzling associations between childhood infections and the later occurrence of asthma and atopy. Ann Acad Med 2000; 32 (6): 397–400.
  3. Булгакова В.А. Персистенция вирусной инфекции при атопической бронхиальной астме у детей. Рос. пед. журн. 2013; 2. [Bulgakova V.A. Persistentsiia virusnoi infektsii pri atopicheskoi bronkhial’noi astme u detei. Ros. ped. zhurn. 2013; 2 (in Russian).]
  4. Симонян Л.Г. Роль вирусов в развитии бронхолегочных заболеваний. Пульмонология. 2014; (2): 105–8. [Simonian L.G. Rol’ virusov v razvitii bronkholegochnykh zabolevanii. Pul’monologiia. 2014; (2): 105–8 (in Russian).]
  5. Вахитов Х.М. и др. Герпетиформная экзема Капоши у ребенка первого года жизни. Казанский мед. журн. 2020; 101 (3): 426–30. [Vakhitov Kh.M. et al. Gerpetiformnaia ekzema Kaposhi u rebenka pervogo goda zhizni. Kazanskii med. zhurn. 2020; 101 (3): 426–30 (in Russian).]
  6. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Eds A. Arvin, G. Campadelli-Fiume et al. Cambridge: Cambridge University Press, 2007.
  7. Исаков В.А., Архипова Е.И., Исаков Д.В. Герпесвирусные инфекции человека. СПб.: СпецЛит, 2013. [Isakov V.A., Arkhipova Ye.I., Isakov D.V. Human herpesvirus infections. SPb.: SpetsLit, 2013 (in Russian).]
  8. Moore KW, Vieira P, Fiorentino DF et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990; 248: 1230–4.
  9. Hsu DH, de Waal Malefyt R, Fiorentino DF et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 1990; 250: 830–2.
  10. Bager P, Westergaard T, Rostgaard K et al. Smallpox vaccination and risk of allergy and asthma. J Allergy Clin Immunol 2003; 111: 1227–31.
  11. Engler RJ, Kenner J, Leung DY. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol 2002; 110: 357–65.
  12. Milgrom H, Palmer E, Leung D. Smallpox vaccination: a conundrum of risks and outcomes. Curr Opin Allergy Clin Immunol 2005; 5: 207–9.
  13. Рабсон А., Ройт А., Делвз П. Основы медицинской иммунологии. 2006. [Rabson A., Royt A., Delves P. Fundamentals of Medical Immunology. 2006 (in Russian).]
  14. Новиков В.В. и др. Растворимые формы мембранных антигенов клеток иммунной системы при социально значимых инфекциях. Сообщение 2. Исследование их роли при вирусных инфекциях. Рос. биотерапевт. журн. 2005; 4 (3). [Novikov V.V. et al. Rastvorimye formy membrannykh antigenov kletok immunnoi sistemy pri sotsial’no znachimykh infektsiiakh. Soobshchenie 2. Issledovanie ikh roli pri virusnykh infektsiiakh. Ros. bioterapevt. zhurn. 2005; 4 (3) (in Russian).]
  15. Мокроносова М.А., Мац А.Н. Инфекция и аллергия: две стороны одной медали. Астма и аллергия. 2015; 4. [Mokronosova M.A., Mats A.N. Infektsiia i allergiia: dve storony odnoi medali. Astma i allergiia. 2015; 4 (in Russian).]
  16. Cabanillas B et al. IgE reactivity against herpes simplex virus 1 in patients with atopic dermatitis complicated by eczema herpeticum. Allergy 2020; 75 (1): 226–9.
  17. Weidinger S, Novak N. Atopic dermatitis. Lancet Lond Engl 2016; 387 (10023): 1109–22. doi: 10.1016/S0140- 6736(15)00149-X
  18. Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. Allergy Asthma Immunol Res 2016; 8 (3): 181–90. doi: 10.4168/aair.2016.8.3.181
  19. Тамразова О.Б., Чеботарева Т.А., Стадникова А.С., Таганов А.В. Клинические проявления инфекции простого герпеса у детей, страдающих атопическим дерматитом. Рос. вестн. перинатологии и педиатрии. 2018; 63 (6): 15–22. doi: 10.21508/1027-4065-2018-63-5-15-22 [Tamrazova O.B., Chebotareva T.A., Stadnikova A.S., Taganov A.V. Clinical manifestations of herpes simplex virus infection in children with atopic dermatitis. Ros. vestn. perinatologii i pediatrii. 2018; 63 (6): 15–22. doi: 10.21508/1027-4065-2018-63-5-15-22 (in Russian).]
  20. Wollenberg A, Bieber T. Atopic dermatitis: from the genes to skin lesions. Allergy 2000; 55: 205–13.
  21. Zaniboni MC, Samorano LP, Orfali RL, Aoki V. Skin barrier in atopic dermatitis: beyond filaggrin. An Bras Dermatol 2016; 91 (4): 472–8. doi: 10.1590/abd1806- 4841.20164412
  22. Gao PS, Rafaels NM, Hand T et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol 2009; 124 (3): 507–13. doi: 10.1016/j.jaci.2009.07.034
  23. O’Neill CA, Garrod D. Tight junction proteins and the epidermis. Exp Dermatol 2011; 20 (2): 88–91. doi: 10.1111/j.1600-0625.2010. 01206.x
  24. Wollenberg A, Wagner M, Günther S et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119 (5): 1096–102.
  25. Leung DY, Gao PS, Grigoryev DN et al. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-gamma response. J Allergy Clin Immunol 2011; 127: 965–973.e5. doi: 10.1016/j.jaci.2011.02.010
  26. Gallo RL, Murakami M, Ohtake T, Zaiou M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 2002; 110: 823–31.
  27. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 2008; 122 (2): 261–6. doi: 10.1016/j.jaci.2008.03.027
  28. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347 (15): 1151–60.
  29. Howell MD, Boguniewicz M, Pastore S et al. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol 2006; 121: 332–8. DOI: 10.1016/j. clim.2006.08.008
  30. Wollenberg A, Zoch C, Wetzel S et al. Predisposing factors and clinical features of eczema herpeticum – a retrospective analysis of 100 cases. J Am Acad Dermatol 2003; 49 (2): 198–205.
  31. Pebody RG, Andrews N, Brown D et al. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sexually Transmitted Infections 2004; 80: 185–91. doi: 10.1136/sti.2003.005850
  32. Umene K, Yoshida M, Sakaoka H. Comparison of the association with eczema herpeticum in the two predominant genotypes of herpes simplex virus type 1. J Med Virol 1996; 49 (4): 329–32.
  33. Yoshida M, Umene K. Close association of predominant genotype of herpes simplex virus type 1 with eczema herpeticum analyzed using restriction fragment length polymorphism of polymerase chain reaction. J Virol Methods 2003; 109: 11–6.
  34. Donald Y, Leung M. Why is eczema herpeticum unexpectedly rare? Antiviral Research 2013; 98: 153–7. DOI: 10.1016/j. antiviral.2013.02.010
  35. Kim K, Kang J, Won Kim S, Sung M. Relationship Between the Presence of Eczema Herpeticum and the Significance of Clinical and Laboratory Tests in Korean Children With Atopic Dermatitis. Iran J Pediatr 2016; 26 (4): e4683. doi: 10.5812/ijp.4683
  36. Hsu DY, Shinkai K, Silverberg JI. Analysisof a Nationwide Cohort. J Invest Dermatol 2018; 138 (2): 265–72. doi: 10.1016/j.jid.2017.08.039
  37. Frisch S, Siegfried EC. The clinical spectrum and therapeutic challenge of eczema herpeticum. Pediatr Dermatol 2011; 28 (1): 46–52. doi: 10.1111/j.1525-1470.2010.01356.x
  38. Beck LA, Boguniewicz M, Hata T et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol 2009; 124 (2): 260–9. doi: 10.1016/j.jaci.2009.05.020
  39. Стадникова А.С., Тамразова О.Б., Чеботарева Т.А. Клинико-эпидемиологические особенности течения экземы Капоши у детей. Педиатрия. Consilium Medicum. 2016; 1: 64–5. [Stadnikova A.S., Tamrazova O.B., Chebotareva T.A. The Case of Herpetic Eczema in a Child with Congenital Ichthyosis and Atopic Dermatitis. Pediatrics. Consilium Medicum. 2016; 1: 64–5 (in Russian).]
  40. Bin L, Kim BE, Brauweiler A et al. Staphylococcus aureus alpha-toxin modulates skin host response to viral infection. J Allergy Clin Immunol 2012; 130 (3): 683–91. doi: 10.1016/j.jaci.2012.06.019
  41. Broccardo CJ, Mahaffey S, Schwarz J et al. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization. J Allergy Clin Immunol 2011; 127 (1): 186–93. doi: 10.1016/j.jaci.2010.10.033
  42. Bauer A, Lange N, Matterne U et al. Efficacy of pimecrolimus 1% cream in the long term management of atopic hand dermatitis. A double-blind RCT. J Dtsch Dermatol Ges 2012; 10 (6): 426–33. doi: 10.1111/j.1610-0387.2011.07832.x
  43. Lubbe J, Pournaras CC, Saurat JH. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatol 2000; 201 (3): 249–51.
  44. Wheeler CJr, Abele DC. Eczema herpeticum, primary and recurrent. Arch Dermatol 1966; 93: 162–73.
  45. Valdes-Rodriguez R, Saavedra-Alanis VM, Islas-Aguilar MA, Torres-Alvarez B. Eczema herpeticum in a patient with atopic dermatitis, carrying r501x and 2282del4 filaggrin null mutations. Gac Med Mex 2015; 151 (2): 252–5.
  46. Leung DYM. Infection in atopic dermatitis. Curr Opin Ped 2003; 15 (4): 399–404.
  47. Ludman S, Du Toit G. Increased complications with atopic dermatitis and varicella-zoster virus. Curr Allergy Clin Immunol 2014; 27 (2): 108–11.
  48. Pandy Kubeyinje E. Varicella Infection In Saudi Children With Atopic Eczema. Med Sci Res 1995; 23 (9): 591–2.
  49. Hoeger PH et al. Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J Infect Dis 1992; 165 (6): 1064–8.
  50. Cho SH et al. Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol 2001; 108 (2): 269–74.
  51. Kita K et al. Activation of bacterial ceramidase by anionic glycerophospholipids: possible involvement in ceramide hydrolysis on atopic skin by Pseudomonas ceramidase. Biochem J 2002; 362 (3): 619–26.
  52. Hori Y. Reduced secretion of IgA to skin surface of patients with atopic dermatitis. J Allergy Clin Immunol 1994.
  53. Silverberg JI, Norowitz KB, Kleiman E et al. Association between varicella zoster virus infection and atopic dermatitis in early and late childhood: A case-control study. J Allergy Clin Immunol 2010; 126 (2): 300–5.
  54. Rystedt I, Strannegard IL, Strannegard O. Infections as contributing factors to atopic dermatitis. Allergy 1989; 44 (Suppl. 9): 79–83.
  55. Kienast AK, Kreth HW, Höger PH. Varicella vaccination in children with atopic eczema. J Deutschen Dermatologischen Gesellschaft 2007; 5 (10): 875–80.
  56. Kreth HW et al. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. Eur J Ped 2006; 165 (10): 677.
  57. Lacour M. Acute infections in atopic dermatitis: a clue for a pathogenic role of a Th1/Th2 imbalance? Dermatology 1994; 188 (4): 255–7.
  58. Fujimura T et al. Conversion of the CD4+ T cell profile from Th2-dominant type to Th1-dominant type after varicella-zoster virus infection in atopic dermatitis. J Allergy Clin Immunol 1997; 100 (2): 274–82.
  59. Goss MA, Beninger PR. Eczema and postvaccination varicella breakthrough. Pediatrics 2005; 116 (6): 1613.
  60. Strannegård IL, Strannegård Ö. Epstein-Barr virus antibodies in children with atopic disease. Int Arch Allergy Immunol 1981; 64 (3): 314–9.
  61. Rystedt I, Strannegård IL, Strannegård Ö. Increased serum levels of antibodies to Epstein-Barr virus in adults with history of atopic dermatitis. Int Archives Allergy Immunol 1984; 75 (2): 179–83.
  62. Горюнова М.М., Петровский А.Н., Мельникова И.Ю. Особенности формирования хронического гастродуоденита у детей с атопическим дерматитом. Клиническая гастроэнтерология. 2010; 1: 137–40. [Goriunova M.M., Petrovskii A.N., Mel’nikova I.Iu. Osobennosti formirovaniia khronicheskogo gastroduodenita u detei s atopicheskim dermatitom. Klinicheskaia gastroenterologiia. 2010; 1: 137–40 (in Russian).]
  63. Турти Т., Яцык Г., Намазова-Баранова Л. Роль внутриутробных вирусных инфекций в формировании атопического статуса у новорожденных детей. Педиатрическая фармакология. 2009; 6 (6): 52–5. [Turti T., Yatsyk G., Namazova-Baranova L. Role of fetal virus infections in shaping atopic status in newborn infants. Pediatric Pharmacology. 2009; 6 (6): 52–5 (in Russian).]
  64. Козлова С.Н., Иванова Л.В. Клинико-иммунологические особенности течения атопического дерматита, ассоциированного с ЦМВ инфекцией и микроэлементный состав крови детей раннего возраста. Пути повышения эффективности медицинской помощи детям. Вопросы современной педиатрии: Материалы Х съезда педиатров России. М., 2005; с. 236. [Kozlova S.N., Ivanova L.V. Clinical and immunological features of the course of atopic dermatitis associated with CMV infection and trace element composition of the blood of young children. Ways to improve the effectiveness of medical care for children. Questions of modern pediatrics: Proceedings of the X Congress of Russian Pediatricians. Moscow, 2005; p. 236 (in Russian).]
  65. Иванова Л.В. Клинико-иммунологические особенности течения атопического дерматита и бронхиальной астмы, ассоциированных с цитомегаловирусной инфекцией. Дис. … канд. мед. наук. Екатеринбург, 2007. [Ivanova L.V. Kliniko-immunologicheskie osobennosti techeniia atopicheskogo dermatita i bronkhial’noi astmy, assotsiirovannykh s tsitomegalovirusnoi infektsiei. Dis. … kand. med. nauk. Ekaterinburg, 2007 (in Russian).]
  66. Hafez SF et al. Active cytomegalovirus infection in patients with atopic dermatitis. Egyptian J Immunol 2005; 12 (2): 1–12.
  67. Mareri A, Adler SP, Nigro G. Herpesvirus-associated acute urticaria: An age matched case-control study. PLoS One 2013; 8 (12): e85378.
  68. Arias-Santiago SA, Almazan-Fernandez FM, Burkhardt-Perez P, Naranjo-Sintes R. Cold urticaria associated with Epstein Barr virus mononucleosis [in Spanish]. Actas Dermosifiliogr 2009; 100: 435–6.
  69. Chin YY, Chang TC, Chang CH. Idiopathic pure sudomotor failure and cholinergic urticaria in a patient after acute infectious mononucleosis infection. Clin Exp Dermatol 2013; 38: 156–9.
  70. Zawar V, Godse K. Recurrent facial urticaria following herpes simplex labialis. Indian J Dermatol 2012; 57 (2): 144.
  71. Zawar V, Godse K, Sankalecha S. Chronic urticaria associated with recurrent genital herpes simplex infection and success of antiviral therapy: A report of two cases. Int J Infect Dis 2010; 14: e514–e517.
  72. Papadopoulos N, Xepapadaki P, Mallia P et al. Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document. Allergy 2007; 62: 457–70.
  73. Царев С.В. Вирусиндуцированная бронхиальная астма: особенности течения и лечебная тактика. Эффективная фармакотерапия. 2015; 20: 26–30. [Tsarev S.V. Virusindutsirovannaia bronkhial’naia astma: osobennosti techeniia i lechebnaia taktika. Effektivnaia farmakoterapiia. 2015; 20: 26–30 (in Russian).]
  74. Махова М.А. и др. Результаты многолетних исследований распространенности вирусов группы герпеса среди детского населения Нижнего Новгорода. Мед. альманах. 2011; 4. [Makhova M.A. et al. Rezul’taty mnogoletnikh issledovanii rasprostranennosti virusov gruppy gerpesa sredi detskogo naseleniia Nizhnego Novgoroda. Med. al’manakh. 2011; 4 (in Russian).]
  75. Суханова Н.А., Цветков Э.А., Новик Г.А. Клиническое значение влияния латентной инфекции верхних дыхательных путей на течение бронхиальной астмы у детей. Педиатрическая фармакология. 2012; 9 (6). [Sukhanova N.A., Tsvetkov E.A., Novik G.A. Klinicheskoe znachenie vliianiia latentnoi infektsii verkhnikh dykhatel’nykh putei na techenie bronkhial’noi astmy u detei. Pediatricheskaia farmakologiia. 2012; 9 (6) (in Russian).]
  76. Супрун Е.Н. Клинико-иммунологические особенности течения бронхиальной астмы с персистенцией цитомегаловируса у детей. Дис. … канд. мед. наук. Хабаровск, 2012. [Suprun E.N. Kliniko-immunologicheskie osobennosti techeniia bronkhial’noi astmy s persistentsiei tsitomegalovirusa u detei. Dis. … kand. med. nauk. Khabarovsk, 2012 (in Russian).]
  77. Конищева А.Ю., Гервазиева В.Б. Вирусы семейства Herpesviridae и аутореактивность у больных бронхиальной астмой. Рос. иммунол. журн. 2019; 22 (2-1): 320–2. doi: 10.31857/S102872210006614-0 [Konishcheva A.Y., Gervazieva V.B. Viral infections from Herpesviridae family and autoreactivity in bronchial ASTHMA. Rus J Immunol. 2019; 22 (2-1): 320–2. doi: 10.31857/S102872210006614-0 (in Russian).]
  78. Schneider L et al. Immune response to Varicella vaccine in children with atopic dermatitis compared to non-atopic controls. J Allergy Clin Immunol 2010; 126 (6): 1306.
  79. Вишнева Е.А., Намазова-Баранова Л.С. Ветрянка прорыва: изменит ли ситуацию новая схема вакцинации? Пед. фармакология. 2011; 8 (6). [Vishneva E.A., Namazova-Baranova L.S. Vetrianka proryva: izmenit li situatsiiu novaia skhema vaktsinatsii? Ped. farmakologiia. 2011; 8 (6) (in Russian).]
  80. Yoo KH, Jacobson Rm, Poland G et al. Asthma status and waning of measles antibody levels concentrations after measles immunization. Pediatr Infect Dis J 2014; 33: 1016–22.
  81. Capili CR, Hettinger A, Rigelman-Hedberg N et al. Increased risk of pertussis in patients with asthma. J Allergy Clin Immunol 2012; 129: 957–63.
  82. Umaretiya PJ et al. Asthma and risk of breakthrough varicella infection in children. Allergy Asthma Proceedings 2016; 37 (3): 207.
  83. Murphy K et al. Antibody response after varicella vaccination in children treated with budesonide inhalation suspension or non‐steroidal conventional asthma therapy. Int J Clin Pract 2006; 60 (12): 1548–57.
  84. Таточенко В.К., Озерецковский Н.А. Иммунопрофилактика-2018. 2018; с. 120. [Tatochenko V.K., Ozeretskovsky N.A. Immunoprophylaxis-2018. 2018; p. 120 (in Russian).]
  85. CDC, Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56 (No. RR-4).
  86. Verstraeten T et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 2003; 112 (2): e98–e103.
  87. Mishra AK, Sahu KK, James A. Disseminated herpes zoster following treatment with benralizumab. Clin Respir J 2019; 13 (3): 189–91.

Statistics

Views

Abstract - 5

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies